Management of high-risk myelodysplastic syndrome

Amer M. Zeidan, Steven D. Gore

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

High-risk myelodysplastic syndromes (HR-MDS) are usually defined by the International Prognostic Scoring System (IPSS) risk classes intermediate-2 and high. Untreated patients with HR-MDS have poor prognosis with a median survival of less than one year. The discovery of the clinically-significant activity of DNA methyltransferase inhibitors (DNMTi) in MDS has been a major advancement. In addition to supportive care, clinical trials, and DNMTi therapy, the typical therapeutic options for HR-MDS include allogeneic hematopoietic stem cell transplantation (alloHSCT) and intensive chemotherapy. Since most patients with HR-MDS are not candidates for alloHSCT due to co-morbidities and lack of appropriate donors, DNMTi therapy has become standard of care first-line therapy for HR-MDS. While not curative, DNMTi therapy results in hematologic improvements including transfusion-independence, delayed leukemic progression, and in case of azacitidine, survival prolongation. Many unanswered questions remain regarding the optimal use of DNMTi therapy. More data is needed about the best schedules, doses, possible combinations and sequencing with other drugs, biomarkers and models to predict response, and duration of therapy. Although several cycles of DNMTi therapy are needed before responses are typically seen, the optimal number of cycles and the role of maintenance therapy after achieving best response need further exploration. The survival advantage in HR-MDS with azacitidine therapy extends to any hematological response, but it is not clear if survival is improved for patients whose best response is stable disease. As more data emerges on the mechanism of action of DNMTi and their effects on methylation, immune system, hematopoietic stem cells, synergism with other agents, the deployment of these agents will likely result in better outcomes in HR-MDS. Patients with primary or secondary resistance to DNMTi therapy have dismal prognosis and very limited therapeutic options. Development of novel agents or ways to restore or prevent emergence of resistance remains a high-priority research area. Understanding the mechanisms of resistance may allow for the rational design of drugs that would prevent emergence of resistance or restore sensitivity to DNMTi therapy. Several novel agents are undergoing evaluation for HR-MDS. The elucidation of the complex pathogenetic mechanisms of the disease will hopefully allow for development for more targeted therapies.

Original languageEnglish (US)
Title of host publicationMyelodysplastic Syndromes, Second Edition
PublisherSpringer Berlin Heidelberg
Pages189-210
Number of pages22
ISBN (Electronic)9783642362293
ISBN (Print)9783642362286
DOIs
StatePublished - Jan 1 2013

Fingerprint

Myelodysplastic Syndromes
Risk Management
Methyltransferases
DNA
Therapeutics
Azacitidine
Survival
Hematopoietic Stem Cell Transplantation
Drug Design
Standard of Care
Hematopoietic Stem Cells
Methylation
Immune System
Appointments and Schedules

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Zeidan, A. M., & Gore, S. D. (2013). Management of high-risk myelodysplastic syndrome. In Myelodysplastic Syndromes, Second Edition (pp. 189-210). Springer Berlin Heidelberg. https://doi.org/10.1007/978-3-642-36229-3_12

Management of high-risk myelodysplastic syndrome. / Zeidan, Amer M.; Gore, Steven D.

Myelodysplastic Syndromes, Second Edition. Springer Berlin Heidelberg, 2013. p. 189-210.

Research output: Chapter in Book/Report/Conference proceedingChapter

Zeidan, AM & Gore, SD 2013, Management of high-risk myelodysplastic syndrome. in Myelodysplastic Syndromes, Second Edition. Springer Berlin Heidelberg, pp. 189-210. https://doi.org/10.1007/978-3-642-36229-3_12
Zeidan AM, Gore SD. Management of high-risk myelodysplastic syndrome. In Myelodysplastic Syndromes, Second Edition. Springer Berlin Heidelberg. 2013. p. 189-210 https://doi.org/10.1007/978-3-642-36229-3_12
Zeidan, Amer M. ; Gore, Steven D. / Management of high-risk myelodysplastic syndrome. Myelodysplastic Syndromes, Second Edition. Springer Berlin Heidelberg, 2013. pp. 189-210
@inbook{d28460b8234743e29d6af54bc7aca1f0,
title = "Management of high-risk myelodysplastic syndrome",
abstract = "High-risk myelodysplastic syndromes (HR-MDS) are usually defined by the International Prognostic Scoring System (IPSS) risk classes intermediate-2 and high. Untreated patients with HR-MDS have poor prognosis with a median survival of less than one year. The discovery of the clinically-significant activity of DNA methyltransferase inhibitors (DNMTi) in MDS has been a major advancement. In addition to supportive care, clinical trials, and DNMTi therapy, the typical therapeutic options for HR-MDS include allogeneic hematopoietic stem cell transplantation (alloHSCT) and intensive chemotherapy. Since most patients with HR-MDS are not candidates for alloHSCT due to co-morbidities and lack of appropriate donors, DNMTi therapy has become standard of care first-line therapy for HR-MDS. While not curative, DNMTi therapy results in hematologic improvements including transfusion-independence, delayed leukemic progression, and in case of azacitidine, survival prolongation. Many unanswered questions remain regarding the optimal use of DNMTi therapy. More data is needed about the best schedules, doses, possible combinations and sequencing with other drugs, biomarkers and models to predict response, and duration of therapy. Although several cycles of DNMTi therapy are needed before responses are typically seen, the optimal number of cycles and the role of maintenance therapy after achieving best response need further exploration. The survival advantage in HR-MDS with azacitidine therapy extends to any hematological response, but it is not clear if survival is improved for patients whose best response is stable disease. As more data emerges on the mechanism of action of DNMTi and their effects on methylation, immune system, hematopoietic stem cells, synergism with other agents, the deployment of these agents will likely result in better outcomes in HR-MDS. Patients with primary or secondary resistance to DNMTi therapy have dismal prognosis and very limited therapeutic options. Development of novel agents or ways to restore or prevent emergence of resistance remains a high-priority research area. Understanding the mechanisms of resistance may allow for the rational design of drugs that would prevent emergence of resistance or restore sensitivity to DNMTi therapy. Several novel agents are undergoing evaluation for HR-MDS. The elucidation of the complex pathogenetic mechanisms of the disease will hopefully allow for development for more targeted therapies.",
author = "Zeidan, {Amer M.} and Gore, {Steven D.}",
year = "2013",
month = "1",
day = "1",
doi = "10.1007/978-3-642-36229-3_12",
language = "English (US)",
isbn = "9783642362286",
pages = "189--210",
booktitle = "Myelodysplastic Syndromes, Second Edition",
publisher = "Springer Berlin Heidelberg",

}

TY - CHAP

T1 - Management of high-risk myelodysplastic syndrome

AU - Zeidan, Amer M.

AU - Gore, Steven D.

PY - 2013/1/1

Y1 - 2013/1/1

N2 - High-risk myelodysplastic syndromes (HR-MDS) are usually defined by the International Prognostic Scoring System (IPSS) risk classes intermediate-2 and high. Untreated patients with HR-MDS have poor prognosis with a median survival of less than one year. The discovery of the clinically-significant activity of DNA methyltransferase inhibitors (DNMTi) in MDS has been a major advancement. In addition to supportive care, clinical trials, and DNMTi therapy, the typical therapeutic options for HR-MDS include allogeneic hematopoietic stem cell transplantation (alloHSCT) and intensive chemotherapy. Since most patients with HR-MDS are not candidates for alloHSCT due to co-morbidities and lack of appropriate donors, DNMTi therapy has become standard of care first-line therapy for HR-MDS. While not curative, DNMTi therapy results in hematologic improvements including transfusion-independence, delayed leukemic progression, and in case of azacitidine, survival prolongation. Many unanswered questions remain regarding the optimal use of DNMTi therapy. More data is needed about the best schedules, doses, possible combinations and sequencing with other drugs, biomarkers and models to predict response, and duration of therapy. Although several cycles of DNMTi therapy are needed before responses are typically seen, the optimal number of cycles and the role of maintenance therapy after achieving best response need further exploration. The survival advantage in HR-MDS with azacitidine therapy extends to any hematological response, but it is not clear if survival is improved for patients whose best response is stable disease. As more data emerges on the mechanism of action of DNMTi and their effects on methylation, immune system, hematopoietic stem cells, synergism with other agents, the deployment of these agents will likely result in better outcomes in HR-MDS. Patients with primary or secondary resistance to DNMTi therapy have dismal prognosis and very limited therapeutic options. Development of novel agents or ways to restore or prevent emergence of resistance remains a high-priority research area. Understanding the mechanisms of resistance may allow for the rational design of drugs that would prevent emergence of resistance or restore sensitivity to DNMTi therapy. Several novel agents are undergoing evaluation for HR-MDS. The elucidation of the complex pathogenetic mechanisms of the disease will hopefully allow for development for more targeted therapies.

AB - High-risk myelodysplastic syndromes (HR-MDS) are usually defined by the International Prognostic Scoring System (IPSS) risk classes intermediate-2 and high. Untreated patients with HR-MDS have poor prognosis with a median survival of less than one year. The discovery of the clinically-significant activity of DNA methyltransferase inhibitors (DNMTi) in MDS has been a major advancement. In addition to supportive care, clinical trials, and DNMTi therapy, the typical therapeutic options for HR-MDS include allogeneic hematopoietic stem cell transplantation (alloHSCT) and intensive chemotherapy. Since most patients with HR-MDS are not candidates for alloHSCT due to co-morbidities and lack of appropriate donors, DNMTi therapy has become standard of care first-line therapy for HR-MDS. While not curative, DNMTi therapy results in hematologic improvements including transfusion-independence, delayed leukemic progression, and in case of azacitidine, survival prolongation. Many unanswered questions remain regarding the optimal use of DNMTi therapy. More data is needed about the best schedules, doses, possible combinations and sequencing with other drugs, biomarkers and models to predict response, and duration of therapy. Although several cycles of DNMTi therapy are needed before responses are typically seen, the optimal number of cycles and the role of maintenance therapy after achieving best response need further exploration. The survival advantage in HR-MDS with azacitidine therapy extends to any hematological response, but it is not clear if survival is improved for patients whose best response is stable disease. As more data emerges on the mechanism of action of DNMTi and their effects on methylation, immune system, hematopoietic stem cells, synergism with other agents, the deployment of these agents will likely result in better outcomes in HR-MDS. Patients with primary or secondary resistance to DNMTi therapy have dismal prognosis and very limited therapeutic options. Development of novel agents or ways to restore or prevent emergence of resistance remains a high-priority research area. Understanding the mechanisms of resistance may allow for the rational design of drugs that would prevent emergence of resistance or restore sensitivity to DNMTi therapy. Several novel agents are undergoing evaluation for HR-MDS. The elucidation of the complex pathogenetic mechanisms of the disease will hopefully allow for development for more targeted therapies.

UR - http://www.scopus.com/inward/record.url?scp=84883557597&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883557597&partnerID=8YFLogxK

U2 - 10.1007/978-3-642-36229-3_12

DO - 10.1007/978-3-642-36229-3_12

M3 - Chapter

AN - SCOPUS:84883557597

SN - 9783642362286

SP - 189

EP - 210

BT - Myelodysplastic Syndromes, Second Edition

PB - Springer Berlin Heidelberg

ER -